The emerging clinical development crisis requires a re-thinking of the entire process.
Waltham, Massachusetts (PRWEB) February 13, 2012
Headlining this year’s OpenClinica Global Conference is Dr. Tomasz Sablinski, a leading clinical research innovator who is challenging the current model of drug development. Dr. Sablinski will talk about how barriers to delivering new medical treatments via clinical development can be overcome by borrowing from contemporary concepts of transparency, crowd sourcing, and open innovation.
Dr. Sablinski’s perspective reflects his 30+ years working as a practicing physician, basic researcher, drug developer, investor, and entrepreneur. During this time, has served as a researcher at Harvard Medical School, a Medical Director at Parexel, VP of Clinical Development at Novartis, and Head of Development and Managing Director at private equity firm Celtic Therapeutics.
According to Dr. Sablinski, “The emerging clinical development crisis requires a re-thinking of the entire process. Those organizations flexible enough to adapt by redesigning the way clinical trials are conceived and conducted using advances in communications and telemedicine, along with open innovation principles, will, I believe, prevail in the long run.”
Dr. Sablinski believes we are at an inflection point--the persistent poor productivity of existing clinical approaches provides a unique opportunity for bringing much- needed innovation to the clinical trials industry.
“We are thrilled to have Dr. Tomasz Sablinski deliver the keynote address at this year’s OpenClinica conference,” said Ben Baumann, Chair of the OpenClinica Conference Committee. “His bold ideas will be sure to challenge many of our current assumptions in thought-provoking, even controversial ways. He is not afraid to question the status quo, and seeks to encourage much of the same type of disruptive innovation that OpenClinica strives to bring to clinical research.”
More information about the 2012 OpenClinica Conference is available online at https://community.openclinica.com/conference.
About the 2012 OpenClinica Conference
Taking place April 22-23, 2012 at the Boston Metro Meeting Center, the OpenClinica Global Conference is an annual gathering of the OpenClinica community focused on sharing information about open source clinical trial software through best practices, case studies, tutorials, and other formats. The event is open to all interested parties (including potential users and existing users) and features content across 3 parallel tracks. The OpenClinica community counts over 14,000 registered individuals with diverse backgrounds, representing biopharmaceutical and device companies, academic organizations, government agencies, contract research organizations, and IT companies. More information about the conference is available online at https://community.openclinica.com/conference.
About Dr. Tomasz Sablinski
Tomasz Sablinski, M.D., Ph.D. is a Founder and CEO of Transparency Life Sciences (TLS), the world’s first drug development company based on open innovation. He is also currently Head of Development and Managing Director of Celtic Therapeutics Development, a global private equity firm that seeks to build one of the most valued late-stage portfolios in the global biomedical industry. Dr. Sablinski founded TLS in 2010, stimulated by opportunities to introduce a new model of drug development afforded by modern computer science technology, new modes of communication, and knowledge generation. He has over 30 years of experience in healthcare and clinical research, including serving as VP of Clinical Development at Novartis and Medical Director at Parexel. His experience in these and other roles includes time in the United States, Europe and Japan. In the 1990s, he was a member of Harvard Medical School (Brigham and Women's and Massachusetts General Hospitals) teams conducting pioneering work in biologic immunosuppressive regimens, induction of transplantation tolerance and xenotransplantation. In parallel, and prior to this, he practiced as a surgeon specializing in renal transplantation and general surgery in his native Poland and in Boston. Transparency Life Sciences’ origins lie in a strong belief that the current system of drug development must be fundamentally changed, and in a passion for helping enable the development of medications at a fraction of current cost. He received his M.D. and Ph.D. from the Academy of Medicine in Warsaw.